|Other Names||Astrocytic phosphoprotein PEA-15, 15 kDa phosphoprotein enriched in astrocytes, Phosphoprotein enriched in diabetes, PED, PEA15|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP8524b was selected from the C-term region of human PEA-15. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Blocks Ras-mediated inhibition of integrin activation and modulates the ERK MAP kinase cascade. Inhibits RPS6KA3 activities by retaining it in the cytoplasm (By similarity). Inhibits both TNFRSF6- and TNFRSF1A-mediated CASP8 activity and apoptosis. Regulates glucose transport by controlling both the content of SLC2A1 glucose transporters on the plasma membrane and the insulin-dependent trafficking of SLC2A4 from the cell interior to the surface.|
|Cellular Location||Cytoplasm. Note=Associated with microtubules|
|Tissue Location||Ubiquitously expressed. Most abundant in tissues such as heart, brain, muscle and adipose tissue which utilize glucose as an energy source. Lower expression in glucose- producing tissues. Higher levels of expression are found in tissues from individuals with type 2 diabetes than in controls|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PEA15 is a death effector domain (DED)-containing protein predominantly expressed in the central nervous system, particularly in astrocytes.
Trencia,A., et.al., Mol. Cell. Biol. 23 (13), 4511-4521 (2003)Sugiyama,N., et.al., Mol. Cell Proteomics 6 (6), 1103-1109 (2007)
If you have any additional inquiries please email technical services at email@example.com.